A pregnant woman with a rapidly growing breast lump

published_or_final_versio

Conservative surgery for breast cancer

Modified radical mastectomy has been the traditional surgical treatment of early breast cancer but in recent years breast conserving surgery has been used with no significant difference in local recurrence and survival rates. This article describes the principle of breast conservation therapy, reviews the outcome of trials of breast conservation therapy and discusses the criteria for selecting patients with early breast cancer for breast conservation therapy. The results of 64 breast conserving surgery performed in Queen Mary Hospital from 1986-1994 are presented. Ten patients (16%) developed local recurrence and seven of them had salvage mastectomy. The five year survival rate was 85%, comparable to Western series.published_or_final_versio

含柴胡的草藥對人類淋巴細胞的影響

Bupleurum-containing compounds, such as KY88 Liver Livo are thought to have immunomodulatory effects. This study investigated the effects of KY88 Liver Livo on the mitogenic induction of lymphocytes in vitro. Fifteen healthy human adult volunteers, aged between 20 and 50 years, provided peripheral blood samples from which lymphocytes were obtained by Ficoll-Hypaque centrifugation. The separated lymphocytes were stimulated by phytohaemagglutinin and KY88 Liver Livo in varying concentrations for 72 hours, with greater cluster and colony formation evident compared with lymphocytes in a control preparation. KY88 Liver Livo was also found to induce the secretion of granulocyte-macrophage colony-stimulating factor in a dose-dependent fashion. These preliminary in vitro studies suggest that KY88 Liver Livo may have potential clinical value in the treatment of chronic viral infection and in the management of immunocompromised patients.published_or_final_versio

Evaluation of Ellagic acid on the activities of oral bacteria with the use of adenosine triphosphate (ATP) bioluminescence assay

Ellagic acid, a natural herb extract from Galla Chinensis in traditional Chinese medicine, shows antimicrobial activity to certain bacteria. The present study evaluated the effect of Ellagic acid on the growth of oral bacteria as well as their generation of water-insoluble glucan and adhesion to salivacoated hydroxyapatite (S-HA) beads. Streptococcus mutans ATCC 25175, Streptococcus sanguis ATCC 10556, Streptococcus salivarius ATCC 25975, Actinomyces naeslundii ATCC 12104, Actinomyces viscosus ATCC 15987, Lactobacillus rhamnosus ATCC 53103, Porphyromonas gingivalis ATCC 33277 and Bacteroides forsythus ATCC 43037 were the bacterial cell lines used in this study. Antibacterial activity of Ellagic acid was determined by using adenosine triphosphate (ATP) bioluminescence assayat various concentrations from 0.125 to 8 mg/ml. Anthrone method was used to evaluate the level of water-insoluble glucan generated by oral bacteria. The numbers of 3H-thymidine labeled bacteria attached to S-HA was counted by scintillation counting method. Sprague Dawley rats were orally fed with 0.5mg/mL ellagic acid for 28 days and their behaviours and excretions were monitored. Ellagic acid reduced bacterial metabolic rates and inhibited the growth of the tested bacterial strains. The waterinsolubleglucan generated by S. mutans and its adhesion to S-HA were reduced. Ellagic acid demonstrated no toxicity in animals fed for 28 days. Ellagic acid might be a promising compound for the development of antimicrobial agents against oral pathogens in human, thereby reducing theincidence of dental caries

mTOR inhibition in breast cancer

No description supplie

Comprehensive characterization of the patient-derived xenograft and the paralleled primary hepatocellular carcinoma cell line

published_or_final_versio

Application of a Nano-antimicrobial film to prevent ventilator-associated pneumonia: A pilot study

Ventilator-associated pneumonia (VAP) is one of the most common hospital-associated infections and has accounted for approximately 15% of all hospital-associated infections. In 76% of the VAP cases, the same bacteria colonize the oral cavity and lungs. Oral care interventions may play a role in the prevention of VAP, yet more than half of the hospitals do not have specific policies for the oral care of intubated patients. Oral cavity interlinks with respiratory tracts and digestive tracts. After surgery has been performed in these areas, aerobic and anaerobic bacteria frequently induce operative wound infections in teeth, gingiva and supporting tissues of the teeth and tonsils. This study investigates the effects of a nanotechnology antimicrobial spray (JUC) on the incidence of VAP. 320 patients diagnosed with VAP were randomly divided into treatment and control groups. After using chlorhexidine mouthrinse, the treatment group used a nanotechnology antimicrobial spray to the nose and mouth. The control group was given normal saline. The incidence rate of VAP was significantly lower in the treatment (8.38%) than control group (54.24%) (p<0.01). A physical antimicrobial film is formed on the surface of oral and nasal mucosa after using the JUC spray which effectively reduces the microbial colonization in the sprayed areas, thus reducing and delaying the incidence of VAP. © 2011 Academic Journals.published_or_final_versio

Cancer genomics and biology 2015 - Meeting report

published_or_final_versio

Antiangiogenic therapy for breast cancer

Angiogenesis is an important component of cancer growth, invasion and metastasis. Therefore, inhibition of angiogenesis is an attractive strategy for treatment of cancer. We describe existing clinical trials of antiangiogenic agents and the challenges facing the clinical development and optimal use of these agents for the treatment of breast cancer. Currently, the most promising approach has been the use of bevacizumab, a humanized monoclonal antibody directed against the most potent pro-angiogenic factor, vascular endothelial growth factor (VEGF). Small molecular inhibitors of VEGF tyrosine kinase activity, such as sorafenib, appear promising. While, the role of sunitinib and inhibitors of mammalian target of rapamycin (mTOR) in breast cancer has to be defined. Several unanswered questions remain, such as choice of drug(s), optimal duration of therapy and patient selection criteria

Clinical trials update: endocrine and biological therapy combinations in the treatment of breast cancer

A greater understanding of the biological mechanisms responsible for de novo and acquired endocrine resistance has led to the rational design of clinical trials exploring the benefit of combining hormonal therapies with novel biological agents in an effort to enhance the efficacy of ER+ breast cancer treatment. These studies are increasingly including parallel biological analyses to elucidate the molecular characteristics of those tumors that are most likely to respond to specific targeted/endocrine combinations in an effort to develop a tailored approach to the management of individual patients. Unfortunately despite encouraging preclinical data, some of these combinations have yielded disappointing results in the clinical setting. This article will review the results of clinical trials of endocrine/biological combinations conducted in early and advanced breast cancer as well as provide an update on ongoing studies